189 related articles for article (PubMed ID: 21773677)
1. Electrocardiographic findings of palonosetron in cancer patients.
Gonullu G; Demircan S; Demirag MK; Erdem D; Yucel I
Support Care Cancer; 2012 Jul; 20(7):1435-9. PubMed ID: 21773677
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Likun Z; Xiang J; Yi B; Xin D; Tao ZL
Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
8. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Brygger L; Herrstedt J;
Expert Opin Drug Saf; 2014 Oct; 13(10):1407-22. PubMed ID: 25196083
[TBL] [Abstract][Full Text] [Related]
10. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Vladimirova LY; Mitashok IS; Storozhakova AE; Kalabanova EA; Svetitskaya YV; Kabanov SN
Vopr Onkol; 2015; 61(4):653-5. PubMed ID: 26571839
[TBL] [Abstract][Full Text] [Related]
11. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
Kim HJ; Lee HC; Jung YS; Lee J; Min JJ; Hong DM; Choi EK; Oh S; Jeon Y
Br J Anaesth; 2014 Mar; 112(3):460-8. PubMed ID: 24129597
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
13. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
Yavas C; Dogan U; Yavas G; Araz M; Ata OY
Support Care Cancer; 2012 Oct; 20(10):2343-7. PubMed ID: 22170340
[TBL] [Abstract][Full Text] [Related]
14. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Fabi A; Malaguti P
Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
[TBL] [Abstract][Full Text] [Related]
15. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron.
Siddiqui MA; Scott LJ
Drugs; 2004; 64(10):1125-32; discussion 1133-4. PubMed ID: 15139789
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hatoum HT; Lin SJ; Buchner D; Cox D
Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
